专利号:US-2024197774-A1 优先权日:2021-04-16 标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles 发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO 权利人:UNIV TEXAS 摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.
专利号:US-12252473-B2 优先权日:2022-04-18 标 题:Preparation methods of quinolone compounds and intermediates thereof 发明人:LEI JIE; CHEN ZHONGZHU; XU ZHIGANG; TANG DIANYONG; XU JIAYU; ZHOU HAOYI; XIA DANDAN; LIU YAO; CAO YIHUA; LUO JIE 权利人:UNIV CHONGQING ARTS & SCIENCES 摘要:The present application relates to processes for the preparation of quinolone compounds and intermediates thereof, particularly to processes for the preparation of quinolones and pharmaceutical intermediates of the quinolones. In particular, the present application provides a process for the preparation of a compound of Formula I, and a process for the synthesis of quinolone compounds using the compound of Formula I as an intermediate. The process for the preparation of the compound of Formula I comprises the steps of:reacting a compound of Formula A with R5NH2 and R6Cl in the presence of a base to form the compound of Formula I,
专利号:WO-2025128098-A1 优先权日:2023-12-13 标 题 :Solid oral dosage forms, kits, and methods of using the same 发明人:LI YING; LANGER ROBERT; TRAVERSO CARLO 权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC 摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).
专利号:US-8093381-B2 优先权日:2007-05-24 标题:Method of synthesis of fluoroquinolones 发明人:BERTHON-CEDILLE LAURENCE; LEGUERN MARIE-EMMANUELLE; RENAUD GILLES; TOMBRET FRANCIS 权利人:BERTHON-CEDILLE LAURENCE; LEGUERN MARIE-EMMANUELLE; RENAUD GILLES; TOMBRET FRANCIS; BIOCODEX 摘要:The invention relates to a method of preparation of fluoroquinolones of formula (I) from compounds of formula (II): n nin which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and X are as defined in Claim 1.
专利号:US-10443047-B2 优先权日:2014-05-01 标题 :Increasing cellular lipid production by increasing the activity of diacylglycerol acyltransferase and decreasing the activity of triacylglycerol lipase 发明人:TSAKRAKLIDES VASILIKI; BREVNOVA ELENA E 权利人:NOVOGY INC 摘要:Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.
专利号:WO-2012149093-A1 优先权日:2011-04-26 标 题 :2-guanidino-4-oxo-imidazoline derivatives as antimalarial agents, synthesis and methods of use thereof 发明人:LIN AI J; LIU XIANJUN; KOZAR MICHAEL P; O'NEIL MICHAEL T 权利人:US OF AMERICA AS REPRESENTED BY THE SECRETARY OF ARMY; LIN AI J; LIU XIANJUN; KOZAR MICHAEL P; O'NEIL MICHAEL T 摘要:The present invention relates to new 2-guanidino-4-oxo-imidazoline derivatives (deoxo-IZ), methods of making these compounds, compositions containing the same, and methods of using the same to prevent, treat, or inhibit malaria in a subject.
1: Watanabe M, Kobayashi M, Ogura J, Takahashi N, Yamaguchi H, Iseki K. Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats. J Pharm Pharm Sci. 2014;17(1):25-33. doi: 10.1128/AAC.02818-14. Epub 2014 May 5. 3: Atkins HS, Spencer S, Brew SD, Jenner DC, Sefton AM, MacMillan AP, Brooks TJ, Simpson AJ. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection. Int J Antimicrob Agents. 2010 Jul;36(1):66-8. doi: 10.1016/j.ijantimicag.2009.10.003. Epub 2009 Dec 21.
合成参考文献
摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664 参考文献:10.2165/00003495-199957060-00002 摘要:Momméja-Marin H, Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections Drugs. 1999 Jun;57(6):851–3. doi: 10.2165/00003495-199957060-00002. 参考文献:10.1191/096032799678840237 摘要:Takizawa T, Hashimoto K, Minami T, Yamashita S, Owen K. The comparative arthropathy of fluoroquinolones in dogs. Hum Exp Toxicol. 1999 Jun;18(6):392–9. doi: 10.1191/096032799678840237. 参考文献:10.1016/s0924-8579(99)00057-6 摘要:Roblin PM, Kutlin A, Reznik T, Hammerschlag MR. Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae. International Journal of Antimicrobial Agents. 1999 Jul;12(2):181–4. doi: 10.1016/s0924-8579(99)00057-6. 参考文献:10.1007/s101560200000 摘要:Niki Y. Pharmacokinetics and safety assessment of tosufloxacin tosilate. J Infect Chemother. 2002 Mar;8(1):1–18. doi: 10.1007/s101560200000.